Rio Mater Research

Rio Mater Research is an early-stage biotechnology company focused on developing novel small molecule therapeutics for inflammatory and metabolic diseases. The company's primary research efforts center on the modulation of G protein-coupled receptor 35 (GPR35), a target with significant implications in mucosal barrier function and intestinal homeostasis. By leveraging deep expertise in GPR35 biology, Rio Mater aims to provide first-in-class treatments for patients suffering from inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. The company is currently advancing its lead programs through pre-clinical validation to address high unmet medical needs in gastrointestinal health.